Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00160602 · ClinicalTrials.gov registry record · Phase 3
A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 590
- Enrollment target
NCT00160602 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 590 participants.
The verdict
NCT00160602, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 590 participants
- Enrollment target
Study Summary
A 24 week study in which patients are given study medication and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study.
Interventions
- DRUG Certolizumab Pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 590 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00160602
The ClinicalTrials.gov registry entry for NCT00160602 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 590 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Certolizumab Pegol is the first listed.
NCT00160602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00160602 about?
NCT00160602 is a clinical study titled "A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis". A 24 week study in which patients are given study medication and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study.
What is the current status of trial NCT00160602?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 590 participants. The study started on 2005-06. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00160602?
The interventions under investigation include: Certolizumab Pegol (DRUG).
Who is sponsoring clinical trial NCT00160602?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.